Payment overview · 2025
General Payments
$90.12
5 reported records · 4 companies
Healthcare provider profile · identity verified
Lawrence J. Watts, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON, NC · NPI 1760427835
Verified facts
What the public records show
CMS Open Payments records show Lawrence J. Watts, MD received $90.12 in general payments during 2025 across 5 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.36 | 30.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.97 | 27.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.47 | 23.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.32 | 18.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.12 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.47 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 431 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 60 |
| Furosemide | Furosemide | 226 | 59 |
| Enalapril Maleate | Enalapril Maleate | 210 | 56 |
| Gabapentin | Gabapentin | 207 | 53 |
| Metformin Hcl | Metformin Hcl | 199 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 55 |
| Omeprazole | Omeprazole | 177 | 51 |
| Losartan Potassium | Losartan Potassium | 163 | 41 |
| Potassium Chloride | Potassium Chloride | 150 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 37 |
| Methylprednisolone | Methylprednisolone | 146 | 99 |
| Eliquis | Apixaban | 141 | 22 |
| Prednisone | Prednisone | 138 | 73 |
| Sertraline Hcl | Sertraline Hcl | 137 | 25 |
| Trazodone Hcl | Trazodone Hcl | 133 | 37 |
| Simvastatin | Simvastatin | 128 | 26 |
| Azithromycin | Azithromycin | 125 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 32 |
| Allopurinol | Allopurinol | 117 | 29 |
| Montelukast Sodium | Montelukast Sodium | 109 | 32 |
| Benazepril Hcl | Benazepril Hcl | 101 | 29 |
| Lorazepam | Lorazepam | 99 | 19 |
| Tramadol Hcl | Tramadol Hcl | 98 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 26 |
| Ezetimibe | Ezetimibe | 97 | 28 |
| Cefdinir | Cefdinir | 92 | 75 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 26 |
| Ozempic | Semaglutide | 87 | 20 |
| Alendronate Sodium | Alendronate Sodium | 85 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 12 |
| Lisinopril | Lisinopril | 85 | 21 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 80 | 17 |
| Sucralfate | Sucralfate | 79 | 18 |
| Mirtazapine | Mirtazapine | 76 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 29 |
| Fenofibrate | Fenofibrate | 73 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 16 |
| Warfarin Sodium | Warfarin Sodium | 69 | suppressed |
| Xarelto | Rivaroxaban | 69 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 17 |
| Lovastatin | Lovastatin | 66 | 19 |
| Terazosin Hcl | Terazosin Hcl | 66 | 18 |
| Repatha Sureclick | Evolocumab | 62 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 11 |
| Glipizide | Glipizide | 61 | 15 |
| Valsartan | Valsartan | 61 | 14 |
| Buspirone Hcl | Buspirone Hcl | 59 | 15 |
| Topiramate | Topiramate | 57 | 17 |
| Atenolol | Atenolol | 54 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Carvedilol | Carvedilol | 53 | 14 |
| Finasteride | Finasteride | 53 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 30 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 49 | 13 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 48 | 14 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Meloxicam | Meloxicam | 48 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 33 |
| Memantine Hcl | Memantine Hcl | 43 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 30 |
| Ketoconazole | Ketoconazole | 38 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Estradiol | Estradiol | 35 | 11 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 28 | 22 |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 21 |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 19 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 12 |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Propylthiouracil | Propylthiouracil | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90.12 · 5 records | Otsuka America Pharmaceutical, Inc. | FREESTYLE LIBRE 3, Leqembi, REXULTI, VOQUEZNA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error